Low Doses of Rituximab in Autoimmune Hemolytic Anemia
Author Information
Author(s): Miriam M. Moser, Renate Thalhammer, Christian Sillaber, Ulla Derhaschnig, Christa Firbas, Ulrich Jäger, Bernd Jilma, Christian Schoergenhofer
Primary Institution: Medical University of Vienna
Hypothesis
In non-malignant diseases, a long-lasting and effective suppression of CD20+ cells may be possible using much lower doses of rituximab.
Conclusion
Low doses of rituximab transiently depleted CD20+ cells in almost all patients, but the tested low-dose regimens were able to permanently suppress CD20+ cells in only a few patients.
Supporting Evidence
- Ten patients were included in the final analysis.
- The first infusion depleted ≥95% of CD20+ cells in all but one of the included patients.
- Rituximab doses as low as 5 mg/m2 transiently depleted CD20+ cells in almost all patients.
Takeaway
This study looked at whether giving very small amounts of a medicine called rituximab could help people with a blood condition. It found that while the medicine worked for a little while, it didn't keep working for most people.
Methodology
This was a phase II, open label, pilot trial investigating the effects and safety of very low doses of rituximab in patients with autoimmune hemolytic anemia.
Limitations
The main limitation of this study is the small sample size, which precludes definitive conclusions on clinical efficacy.
Participant Demographics
{"mean_age":69,"sex_distribution":{"female":7,"male":3},"types_of_AIHA":{"warm_AIHA":2,"cold_agglutinin_disease":7,"mixed_type_AIHA":1}}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website